News Reader.info

ABSTRACT Preclinical studies have revealed that the elevation of nicotinamide adenine dinucleotide (NAD + ) upon the administration of nicotinamide mononucleotide (NMN), an NAD + precursor,

can mitigate aging-related disorders; however, human data on this are limited. We investigated whether the chronic oral supplementation of NMN can elevate blood NAD + levels and alter

physiological dysfunctions in healthy older participants. We administered 250 mg NMN per day to aged men for 6 or 12 weeks in a placebo-controlled, randomized, double-blind, parallel-group

trial. Chronic NMN supplementation was well tolerated and caused no significant deleterious effect. Metabolomic analysis of whole blood samples demonstrated that oral NMN supplementation

significantly increased the NAD + and NAD + metabolite concentrations. There were nominally significant improvements in gait speed and performance in the left grip test, which should be

validated in larger studies; however, NMN exerted no significant effect on body composition. Therefore, chronic oral NMN supplementation can be an efficient NAD + booster for preventing

aging-related muscle dysfunctions in humans. SIMILAR CONTENT BEING VIEWED BY OTHERS HEALTHY AGING AND MUSCLE FUNCTION ARE POSITIVELY ASSOCIATED WITH NAD+ ABUNDANCE IN HUMANS Article 17

February 2022 NICOTINAMIDE ADENINE DINUCLEOTIDE METABOLISM AND ARTERIAL STIFFNESS AFTER LONG-TERM NICOTINAMIDE MONONUCLEOTIDE SUPPLEMENTATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED

TRIAL Article Open access 16 February 2023 NICOTINAMIDE N-METHYLTRANSFERASE INHIBITION MIMICS AND BOOSTS EXERCISE-MEDIATED IMPROVEMENTS IN MUSCLE FUNCTION IN AGED MICE Article Open access 05

July 2024 INTRODUCTION Aging is a risk factor for diabetes, cardiovascular diseases, cancer, and neurological diseases, such as Alzheimer’s disease, and the suppression of physiological

decline in aging is an important approach to prevent aging-related diseases1. Aging- and age-related diseases have been shown to be closely related to decreased NAD + levels2. In animal

studies, the administration of intermediate NAD + metabolites, such as nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinamide riboside (NR), has been shown to increase NAD + 

concentrations, which helped improve the health and extend the lifespan of the experimental animals2,3,4,5,6. Thus, the potential of intermediate NAD + metabolites in improving tissue

rejuvenation in humans has led to multiple clinical trials on NR and NMN. NR, a vitamin B3 analog, is a major vitamin component present in milk (~1 mg/L)7. NMN is present in foods such as

edamame, broccoli, and meat (~1 mg/100 g food)8. However, owing to their extremely low concentrations in foods, it is difficult to obtain these components in sufficient quantity from food.

Therefore, purified and concentrated NR and NMN have been used in clinical trials. The results of NR clinical trials have been reported. In these trials, NR (100–2000 mg/day) was

administered to healthy participants or individuals with obesity for a maximum of 12 weeks9,10,11,12,13,14,15,16,17,18,19. Most NR clinical trials have reported the safety of NR

administration9,10,11,12,13,14,15,16,17,18 and the elevation of NAD + or NAD + -related metabolites in the blood9,10,11,12,13,14,15,16,17. The most recent report showed that NR increases the

fat-free body mass in participants with obesity, although no effect was observed on insulin sensitivity, mitochondrial function, and hepatic and intramyocellular lipid accumulation17.

Recently, for the first time, the safety of single-day NMN oral administration was reported in humans20. Moreover, while the drafting of this paper was underway, a 10-week, randomized,

placebo-controlled, double-blind trial to evaluate the effect of NMN supplementation on metabolic function in 25 postmenopausal women with prediabetes was reported21, in which NMN

supplementation increased muscle insulin sensitivity, insulin signaling, and remodeling in women with prediabetes who are overweight or obese21. Furthermore, the effects of NMN

supplementation combined with exercise training have been reported in healthy amateur runners aged 27–50 years22. NMN dose-dependently increased the ventilatory threshold and improved

aerobic capacity during exercise22. However, evidence of the effects of human interventions with NMN remains limited for older adults. Therefore, to elucidate the safety and efficacy of NMN

administration in older adults, we conducted a placebo-controlled, randomized, double-blind, parallel-group study with the administration of 250 mg of NMN to healthy men aged 65 years or

more for 12 weeks. We demonstrated that NMN oral supplementation at 250 mg/day in healthy older men for 12 weeks was safe and well-tolerated and significantly increased the levels of NAD + 

and NAD +-related metabolites in whole blood. Furthermore, NMN administration partly improved muscle performance, evaluated using gait speed and grip strength, in healthy older men. Thus,

the chronic oral administration of NMN could be a therapeutic strategy for aging-related disorders in humans, such as sarcopenia. RESULTS PARTICIPANT ENROLLMENT AND BASELINE CHARACTERISTICS

Sixty-five men of age 65 years or more were screened for the study, which was conducted between July 2019 and November 2019 and registered on UMIN-CTR under the identifier UMIN000036321.

Eight participants were excluded owing to specific medical history or abnormal laboratory data. Three participants were enrolled in other clinical trials after the obtainment of consent. Two

participants were excluded because they requested to withdraw immediately after providing consent. The 42 enrolled participants were randomized between the two treatment groups (placebo

group and 250 mg NMN/day group) (Fig. 1). The supplements (placebo or NMN) were supplied to each group of participants at 0- and 6-week visits. However, after the completion of the study, it

came to light that at the 6-week visit, 11 participants each in the NMN and placebo groups received the other supplement owing to an error made by the supplier. According to the decision of

the Ethics Committee of the University of Tokyo Hospital, we decided to exclude the data acquired from the 22 participants during the 12-week visit (Fig. 1). The main physical and metabolic

features of the NMN (_n_ = 21) and placebo groups (_n_ = 21) are summarized in Table 1. Key parameters were comparable between the two groups at baseline. Excluding the data for 22

participants, the physical characteristics of all participants in the NMN and placebo groups at baseline are shown in Supplementary Table S1. SUPPLEMENTATION OF 250 MG/DAY NMN FOR 12 WEEKS

IS WELL TOLERATED We observed excellent adherence to the study treatment, with all participants consuming more than 90% of all NMN and placebo supplements administered. NMN (250 mg/day) was

well-tolerated, and no serious adverse event occurred. Clinical laboratory values were obtained from blood samples collected at baseline and at the 12-week visit. No significant difference

was observed between the NMN and placebo groups with respect to hematological and blood chemistry parameters, including liver enzymes and renal function markers (Supplementary Tables S2 and

S3). Importantly, all clinical laboratory values were within the normal range in the NMN group. These results indicated that NMN supplementation at 250 mg/day for 12 weeks is well tolerated

in healthy older men. CHRONIC ORAL ADMINISTRATION OF NMN INCREASES THE LEVELS OF NAD+ AND NAD+-RELATED METABOLITES IN WHOLE BLOOD Whole blood samples were collected at baseline and at the

12-week visit from participants for the subsequent analysis of NAD+ and NAD+-related metabolites using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Oral NMN supplementation

effectively elevated the levels of NMN and NAD+ as compared to placebo supplementation (Fig. 2 and Supplementary Table S4). We also observed an increase in NR, which could indicate the

possible conversion of NMN to NR by CD7323. Notably, NMN also significantly elevated the levels of nicotinic acid mononucleotide (NAMN) (an intermediate of the NAD+ de novo synthesis

pathway) and nicotinic acid riboside (NAR). Collectively, these findings indicate that the chronic oral supplementation of NMN effectively stimulates NAD+ metabolism in healthy older men.

CHRONIC ORAL ADMINISTRATION OF NMN PARTLY IMPROVES MOTOR FUNCTIONS To examine the effects of NMN oral administration on skeletal muscle mass in healthy older men, the skeletal mass index

(SMI) and segmental lean mass (lean trunk, arms, and legs) were measured using bioimpedance analysis (BIA), and as the primary analysis, the mean values in the NMN and placebo groups at

baseline and the 6- and 12-week visits were evaluated using mixed-model analysis or the mixed-effect model for repeated measures (MMRM)24. In addition, the means of each group at both visits

were compared using the Mann–Whitney _U_ test for non-normal distribution and _t_ tests for normal distribution. Furthermore, the difference between pre- and post-placebo and pre- and

post-NMN supplementation (ΔPlacebo and ΔNMN, respectively) groups at the 6-and 12-week visits were analyzed using ANCOVA. No significant difference was observed in the skeletal muscle mass

in any of these analyses (Table 2). Conversely, to examine muscle strength and performance, gait speed, counts in the 30-s chair-stand test, and grip strength were assessed and analyzed

using the same statistical method (Table 3). Mixed-model analysis or MMRM showed a significant improvement in the gait speed (_P_ = 0.033) and left grip test (_P_ = 0.019) after NMN

administration (Table 3). These findings indicate that the chronic oral supplementation of NMN partly improved the muscle strength and performance in healthy older men, although NMN did not

affect the skeletal muscle mass. We also observed a significant difference between the mean gait speed values of each group during the 6-and 12-week visits (_P_ = 0.023 and _P_ = 0.002,

respectively). Furthermore, a significant difference was observed in the results of the 30-second chair-stand test between the ΔPlacebo and ΔNMN groups at the 6-week visit (_P_ = 0.031).

LIVER AND VISCERAL FAT MASS ARE NOT AFFECTED BY NMN SUPPLEMENTATION Next, we investigated the effect of NMN on fat mass distribution, because findings from animal studies suggest the

positive effect of NMN on insulin sensitivity and hepatic steatosis3,4 (Fig. 3). Chronic NMN supplementation did not affect the visceral fat area (Fig. 3a) and CT values of the liver and

spleen (L/S ratio) in the computed tomography (CT) scan (Fig. 3b), in accordance with the measurement of fat mass using BIA (Fig. 3b). Likewise, NMN administration did not affect the

homeostatic model assessment of insulin resistance (HOMA-IR), an indicator of hepatic insulin sensitivity in blood analysis (Fig. 3c). Adiponectin and interleukin (IL) 6, which are also

related to insulin sensitivity, were unaffected by NMN administration (Supplementary Table S5). These data indicate that insulin sensitivity and fat mass were unaffected by NMN

supplementation in our study. Consistently, no significant difference or trend of change was observed in the triglyceride, LDL-cholesterol, HDL-cholesterol, HbA1c, FBG, HOMA-β, insulin, and

C-peptide levels and the area under the curve (AUC) for glucose in 75 g of the sample using the oral glucose tolerance test (OGTT) after NMN supplementation (Fig. 3c and Supplementary Table

S5). EFFECT OF NMN ON OTHER AGING-RELATED PHENOTYPES To gain exploratory insights into the potential benefits of NMN supplementation on other domains of physiological functions in healthy

older men, we assessed a wide variety of outcomes indicative of sensory, vascular, and cognitive functions. Audibility tended to improve in the right ear, although the change was not

statistically significant (_P_ = 0.054, mixed-model analysis) (Supplementary Table S6). Conversely, no difference was observed in the indicators of vascular functions, such as assessed blood

pressure and flow-mediated dilation (Supplementary Table S7). Lastly, the intervention exerted no observable effect on overall cognitive function, as assessed using the mini-mental state

examination-Japanese (MMSE-J) and the Japanese version of the Montreal Cognitive Assessment (MOCA-J) (Supplementary Table S6). DISCUSSION In this study, we reported that the chronic oral

supplementation of 250 mg of NMN per day is safe and a well-tolerated and effective strategy for boosting NAD+ metabolism in healthy older men. In addition, our exploratory analyses of the

effects of NMN supplementation on physiological functions suggest NMN improves muscle strength, which is an important clinical indicator of aging. When this study was designed, the results

of the NMN clinical trial were not available. Some studies have reported the effects of oral or intraperitoneal NMN administration (100–500 mg/kg/day) in mice3,4. Particularly, the long-term

administration of NMN at doses of 100 or 300 mg/kg/day for 1 year caused no significant side effect and improved insulin sensitivity and eye functions8. If this dosage is expressed in terms

of the absorption area in the small intestine, 100 mg/kg/day NMN in mice is considered equivalent to an intake of 8 mg/kg/day in humans25. Some human clinical studies have been conducted in

Japan and the USA. In the study performed in the USA21, NMN was administered at 250 mg/day for 10 weeks, and in the study performed in Japan (UMIN ID UMIN000025739), it was administered at

100 or 200 mg/day for 24 weeks. Additionally, several human clinical trials have been conducted on NR, another precursor of NAD+, in which NR has been administered at doses of 100–2000

mg/day for up to 12 weeks, with no serious side effects reported9,10,11,12,13,14,15,16,17,18,19. The NMN dose in this study was fixed after considering the dose in previously reported NR

trials (100–2000 mg/day) and ongoing NMN clinical trials (100, 200, and 250 mg/day). In a previous NMN study, a single oral dose of 500 mg NMN20 and the 10-week chronic administration of 250

 mg NMN21 did not induce any specific deleterious side effects. In the most recent study, the chronic administration of 1200 mg of NMN per day for 6 weeks did not cause any significant

adverse events22. Likewise, the 12-week chronic administration of 250 mg of NMN in this study also exerted no significant side effect. NR has been demonstrated to be well-tolerated in all

published clinical studies9,10,11,12,13,14,15,16,17,18,19, whereas nicotinic acid (NA) has been demonstrated to induce nausea and flushing, which leads to difficulties in the administration

of high doses of NA for increasing NAD+ levels26. NAM, another NAD+ precursor, has also been reported to induce hepatotoxicity27; however, we did not find any abnormality in the clinical

laboratory values, including those of liver or muscle enzymes, in our study. Overall, NMN was well tolerated up to a chronic dose of 250 mg. Previous studies have reported that NR

administration significantly increases the plasma or whole blood NAD+ levels in healthy participants9,10,11,12,15,16. Conversely, a recent NMN study21 showed the direct detection of an

increase in the blood NAD+ levels, although the muscle NAD+ content remained unaltered, after 10 weeks of treatment21. Thus, this is the second study to report that NMN administration

significantly increased the levels of NAD+ and NAD+ metabolites in whole blood. An unexpected finding was a considerable elevation in the NAMN and NAR levels, which was not an en route for

the conversion of NMN to NAD+. The previous report has proposed that as the rate of NAD+ synthesis increases, the deamidation of NAD+ to nicotinic acid adenine dinucleotide (NAAD) can occur

in competition with NAD+ turnover to nicotinamide, suggesting that NAAD can serve as a sensitive biomarker for increased NAD+ metabolism9. Alternatively, an increase in NAD+ can result in

NMN deamidation, leading to the formation of NAMN. Another mechanism could be the deamidation of NMN by gut microbiota. Oral NAM or NR can be deamidated into NA, NAR, NAAD, and NAMN by gut

microbiota in the small intestine and colon28. Deamidated NAD+ metabolites move to the tissues via circulation, contributing to NAD+ synthesis28. Skeletal muscle mass and strength decrease

with aging because of muscle atrophy, eventually lowering the quality of life29. The application of NMN in vivo has been shown to ameliorate muscle decline in rodent models3,4. NMN has also

been reported to improve mitochondrial functions in the skeletal muscles of rodents3,4,30. In agreement with the evidence reported in rodents, we found that chronic NMN supplementation

partly improved muscle strength and performance in older men, which was evaluated using gait speed and grip strength; however, further investigation is needed to determine the difference

between the effects of NMN on the left- and right-side grip strengths. Gait speed and grip strength are included in the diagnostic criteria for sarcopenia (aging-related loss of muscle mass

and function), such as AWGS (Asian Working Group for Sarcopenia) or EWGSOP (European Working Group on Sarcopenia in Older People), and are known to be adequately sensitive for the assessment

of muscle strength and performance in older adults. Therefore, we believe that the chronic oral administration of NMN is a potential therapeutic strategy for sarcopenia. Moreover, we

speculate the grip strength with significance only on the left side might make a significant difference on the other side, if there are more participants. Since ~90% of Japanese people are

right-handed, the effect of NMN supplementation might be more pronounced in the left hand, which is less affected by daily exercise and movement. Contrary to the findings of the animal

study, in which 300 mg/kg/day NMN tended to increase lean mass, as compared to that in the controls9, NMN did not affect the skeletal muscle mass of participants in our study. To examine

whether our sample size was adequately large for detecting the significance of the primary endpoint, SMI, the statistical power was calculated post hoc. The standard deviation for the change

in SMI at 12 weeks was 0.22 kg/m2 (Table 2). The value for an expected change in SMI owing to NMN intake was set at 0.45 kg/m2 (6–7% of baseline), based on a preliminary study on Japanese

older men31,32. Based on these parameters, the power was calculated to be 0.991 using a two-sided test (α = 0.05 and total sample size = 20). These results indicate that the data had

adequate power to determine the expected effect of NMN on SMI, even when considering the exclusion of data for 22 participants on the 12-week visit, and our data clearly rejected the

hypothesis that the true effect size of NMN on SMI is 0.45 kg/m2 or more. Since amino acid supplementation for 12 weeks was adequate for improving muscle mass and strength in some

reports33,34, the period of our study was not too short for reporting muscle hypertrophy, although we cannot reject the possibility that the change in skeletal muscle mass would be observed

more clearly if the experiment extended beyond 12 weeks. Recently, several NR human studies have reported that the mitochondrial functions in skeletal muscle cells do not increase following

NR supplementation16,17,19. While our findings suggest that the chronic supplementation of NMN may support overall muscle health, further studies are warranted to elucidate the mechanisms

underlying the observed increase in mobility. NMN supplementation has also been suggested to improve insulin sensitivity and metabolic health in rodent models3,4. A previous NR human study

reported a decrease in hepatic lipid content in men with obesity, although the decrease was not significant13. Furthermore, the recent study on NMN has reported insulin-stimulated glucose

disposal, assessed using an hyperinsulinemic-euglycemic clamp, and increased skeletal muscle insulin signaling in response to NMN supplementation21. In this study, NMN exerted no effect on

hepatic lipid accumulation and insulin sensitivity. This may be attributed to the normal metabolic status of our study population. In this study, we also performed a preliminary evaluation

of the auditory capacity of participants using an audiometer before and after the intervention with NMN. In mice, SIRT3, an NAD+-dependent protein deacetylase localized to the mitochondria,

is reportedly involved in the regulation of hearing ability during aging35. NR supplementation in rodents has also been reported to improve noise-induced and age-related hearing loss via

SIRT3 activation35,36,37. In our study, NMN supplementation partly tended to improve the auditory capacity of older people. However, there is limited information about the underlying

mechanisms by which NAD + precursors may improve hearing in humans. Based on findings from preclinical studies35,36,37,38, NMN could similarly affect hearing in humans through mechanisms

involving SIRT3 activation and the increased reduced-to-oxidized glutathione ratio in the mitochondria. However, in future, mechanistic studies are needed to test this hypothesis. Such

studies will be technically challenging in humans, and it will be important to dissociate the effects of SIRT3 activation from the possible pleiotropic effects of the elevation of NAD+

metabolites. While this study offers novel insights into NMN as a nutritional supplement and potential therapeutic entity, it has some limitations. First, the 42 enrolled participants were

randomized between the two treatment groups that were adjusted for age, body mass index (BMI), and SMI. However, data from 22 participants were excluded, owing to which the adjustment

between the two groups was disrupted, which may have compromised some results in this study. Further investigation will be needed to apply our findings to all older men, although the

statistical analyses were valid for the population analyzed in this trial. Second, as all analyses were exploratory, and the primary analysis for each endpoint was specified, multiple

comparisons were performed only without _P_ value correction. Although the statistical analyses performed were valid for the population analyzed in this trial, further investigation is

needed to confirm our findings. Third, we included only healthy older men in this study. Older participants were included in the study because NAD+ levels decrease with age in rodents and

humans39, and NAD+ supplementation can be more effective in older people. Moreover, only male participants were selected, considering the possibility that data from older females may be

affected by the rapid decrease in estrogen or progesterone levels associated with menopause. We speculate that NMN administration might be effective in different populations, such as

middle-aged adults or older women, because the apparent difference in the response to NR, another NAD+ precursor, owing to age or sex, has not been reported in human clinical

studies9,10,11,12,13,14,15,16,17,18,19. However, it remains to be determined whether NMN supplementation is effective in populations that are heterogeneous with respect to gender, age, or

baseline physiological functions, which is critical in determining the therapeutic potential of oral NMN supplementation. Thus, further clinical studies should be conducted in specific

populations in this regard. METHODS ETHICAL APPROVAL, INFORMED CONSENT, AND STUDY LOCATION The study was conducted in accordance with the guidelines of the Declaration of Helsinki and was

approved by the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo Research Ethics Committee (2018013P). The study was registered at UMIN-CTR (UMIN000036321) before

the patients were recruited. The participants received oral and written information before they provided written consent. The study was conducted at the Clinical Research Support Center

Phase 1 Unit at the University of Tokyo Hospital. STUDY DESIGN, RANDOMIZATION, AND INTERVENTION The study was designed as a placebo-controlled, randomized, double-blind, parallel-group

trial. Participants were examined at baseline and the 6-week and 12-week visits. After completion of the baseline investigations, participants were randomized to a 12-week supplementation of

NMN or a placebo, with daily administration by a third party, C&C QUALITATIVE RESEARCH INSTITUTE INC (Tokyo, Japan); there were no significant differences in age, BMI, or SMI between

the two groups (Table 1). The allocation to the NMN or placebo group was also managed by C&C QUALITATIVE RESEARCH INSTITUTE INC until the end of the study. The participants received oral

supplementation of 250 mg of NMN (Mitsubishi Corporation Life Sciences Limited, Tokyo, Japan) once daily or a placebo for 12 weeks. The participants and data collectors were blinded to the

treatment. Once all participants completed the study, the randomization code was released. The primary objective of this study was to evaluate the potential benefits of NMN in increasing

blood NAD + concentration and its effects on the body composition of older participants after the 12-week treatment. The secondary objective of the study was to evaluate aging-related

parameters, such as muscle strength and performance, bone density, vision, and hearing ability. STUDY PARTICIPANTS Sixty-five healthy Japanese male volunteers were recruited in the study.

The inclusion criteria were as follows: male, aged more than 65 years, BMI (in kg/m2) 22–28, nonsmokers, and without any active diseases. Participants with a history of treatment for

malignancy, heart failure, or myocardial infarction; consuming a prescription medication and/or supplement that may affect the findings of clinical research; or with a habit of daily

exercise for at least 1 h for a minimum of 6 months continuously were excluded. The participants underwent a physical examination by a physician, including routine clinical biochemistry

tests, to evaluate their eligibility for the study. During the intervention, participants were instructed not to change their lifestyle and to abstain from vitamin B3-related dietary

supplements. Eventually, 20 participants completed the study, and 22 dropped out because of an error in the distribution of NMN or placebo at the 6-week visit (Fig. 1). EVALUATION OF SAFETY,

TOLERABILITY, AND ADHERENCE Participants were instructed to record any adverse event in a diary, and during each visit, they were asked about any difficulty or problem they had experienced

since the previous visit. Participants were also requested to immediately report any serious adverse event during the study to the investigators. Adverse events were monitored via a blood

test and by observing the participants during safety checkups at the 6- and 12-week visits. Adherence was checked using the pill count. LABORATORY MEASUREMENTS Blood was collected from the

forearm of each participant at baseline and the 12-week visit. Hematological parameters, including white blood cell count, red blood cell count, hemoglobin, hematocrit level, platelet count,

mean red blood cell pigment content, mean red blood cell volume, and mean red blood cell pigment concentration, were measured. An OGTT was performed using 75 g of glucose. The blood

glucose, insulin, and C-peptide levels were measured at 0, 30, 60, and 120 min after oral glucose loading. The AUCs for glucose, insulin, and C-peptide were calculated using the trapezoidal

formula. Insulin resistance, determined using HOMA-IR, was calculated using the following equation: fasting glucose (mg/dL) × fasting insulin (µU/mL)/405. HOMA-β was calculated using the

following formula: 360 × fasting insulin (µU/mL)/(fasting glucose (mg/dL) − 63). The levels of biochemical parameters, including triglyceride, total cholesterol, LDL-cholesterol,

HDL-cholesterol, glucose, HbA1c, insulin, blood C-peptide, AST, ALT, γ-GTP, CK, total protein, albumin, uric acid, uric acid nitrogen, creatinine, sodium, potassium, high-sensitivity

C-reactive protein, adiponectin, and IL-6, were measured. For adiponectin and IL-6, blood samples were left to stand for 30 min, centrifuged at 25 °C and 1800×_g_ for 5 min, and stored at

−30 °C. Blood samples for adiponectin and IL-6 were dispatched to SRL, Inc. (Tokyo, Japan) for testing. Other blood tests were performed at the University of Tokyo Hospital. EXTRACTION OF

NAD+ AND LC-MS ANALYSIS At baseline and the 12-week visit, blood samples were collected in heparinized tubes, frozen at −80 °C, and analyzed at the University of Toyama40. Metabolites were

extracted by mixing 50 µL of blood and 450 µL of MeOH, which was followed by vortexing for 10 s. An equal volume of chloroform was added to the solution. The mixture was centrifuged at

13,000×_g_ at 4 °C for 10 min. The separated upper aqueous phase was transferred into a new tube, and the same procedure was repeated. The aqueous phase was dried and reconstituted in

LC/MS-grade water. Metabolites were analyzed using an Agilent 6460 Triple Quad mass spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA) coupled with an Agilent 1290 HPLC system

(Agilent Technologies Inc.). Analytes were separated on an Atlantis T3 column (2.1 × 150 mm, particle size 3 µm, Waters) using mobile phase A (5 mM ammonium formate) and mobile phase B

(methanol) with a flow rate of 150 µL/min and column temperature of 40 °C. The programmed mobile phase gradient was as follows: 0–10 min, 0%–70% B; 10–15 min, 70% B; 15–20 min, 0% B. Data

were analyzed using the MassHunter Quantitative Analysis software (Agilent Technologies Inc). A standard curve was obtained using various concentrations of the standard compounds and used

for quantification. BODY COMPOSITION A direct segmental multifrequency bioelectrical impedance analyzer (InBody S10®; InBody Japan Inc., Tokyo, Japan) was used to determine the body

composition of the participants. We recorded the whole-body skeletal muscle mass, segmental lean (right arm, left arm, trunk, right leg, and right leg), fat mass, and body fat percentage at

baseline, 6 weeks, and 12 weeks. SMI was calculated by dividing the whole-body skeletal muscle mass by the square of height (kg/m2). CT Abdominal CT was performed to assess the liver and

visceral fat (Aquilion PRIME/TSX-303A/BI, Aquilion Precison/TSX-304A/2A, Aquilion ONE/TSX-101A Vision Edition) at baseline and at the 12-week visit. The ratio of the CT values of the liver

and spleen (L/S ratio) was evaluated to assess liver fat using the images on a Centricity RA1000 workstation (GE Healthcare, Chicago, IL, USA). Three circular or ovoid regions of interest

(ROIs) (diameter, ~15 mm) in the liver were placed on the left lobe and ventral and dorsal parts of the right lobe at the level of the umbilical portion of the portal vein. In contrast, two

ROIs in the spleen were placed on the ventral and dorsal parts of the spleen at its maximum diameter. The apparent main vasculature, bile duct, and calcification were avoided when the ROIs

were placed in each image set. The CT values and standard deviations (i.e., image noise) were recorded after placing the ROIs on each image. The CT value (L/S) was calculated as the ratio of

the mean CT values of three ROIs in the liver (CT[L]) to that of two ROIs in the spleen (CT[S]). Visceral fat was assessed using Fat Scan (East Japan Institute of Technology Co., Ltd.

Ibaraki, Japan). The visceral fat area was measured in the slice at the umbilicus (Fig. 3)41. ASSESSMENT OF EXERCISE CAPACITY AND PHYSICAL FUNCTION To evaluate physical functions, the

participants were tested for gait speed, grip strength, and 30-s chair-stand test at baseline and at the 6- and 12-week visits. Gait speed was assessed using a 10 m walk test with 3 m

provided for acceleration/deceleration. While a participant walked about 16 m, the time was measured for walking the intermediate 10 m. The average of two measurements was used as the

outcome data. Grip strength was measured using a Smedley-type digital hand dynamometer (Grip D®; Matsuyoshi & Co., Ltd., Tokyo, Japan). Measurements were repeated twice for each hand.

The highest handgrip strength value was used for calculations. The 30-s chair-stand test measures the number of times a participant stood up and sitting down from the standard chair without

armrests in 30 s. Participants were initially seated on the chair with their back in an upright position and were instructed to look straight forward and to rise with their arms folded.

HEARING TESTS The hearing ability of both ears was measured using an audiometer (Audiometer AA-79, RION Co., Ltd.) at baseline and at the 12-week visit. In the hearing test, only air

conduction was measured, and the pure tone hearing level averages of 500, 1000×2, and 2000 Hz were evaluated. COGNITIVE FUNCTION TEST MMSE-J and MOCA-J were performed to assess the cognitive

performance of the participants at the beginning of the study and after the 12-week intervention42,43. FLOW-MEDIATED DILATION After 10 min of rest, a blood flow-dependent vasodilatation

response test was performed using a vascular ultrasound system (UNEX EF 18VG, UNEX Corporation) at baseline and at the 6- and 12-week visits. When the cuff was used to stop and release the

blood flow from the forearm, the extent of blood vessel dilation was measured as the percentage of vessel diameter dilatation (lrb%). STATISTICAL ANALYSIS Statistical analysis was performed

using Easy R for Microsoft Windows44 and R version 4.0.2 (2020-06-22) with the data collected at baseline (_N_ = 21) and at the 6-week (_N_ = 21) and 12-week (_N_ = 10) visits in the NMN or

placebo group. Outcome data are reported in terms of mean ± standard deviation. For comparisons between the NMN and placebo groups, for each outcome datum, the Shapiro–Wilk test was used as

the normality test. Data that followed a normal distribution were analyzed using an unpaired _t_ test. Changes in the NMN and placebo groups from baseline to Week 6 or Week 12 were compared

using ANCOVA to adjust for baseline. Data that did not follow normal distribution were compared using the Mann–Whitney _U_ test. Owing to the exclusion of data in consideration of the errors

in NMN or placebo allocation, treatment comparison was performed using mixed-model analysis, in which intercept and visit were included as random effects, and group, visit, and

group-by-visit interaction were included as fixed effects. As some endpoints could not be calculated using mixed-model analysis, all endpoints were calculated using MMRM, in which the group,

visit, and group-by-visit interaction were considered the fixed effects. The values of the outcomes at the baseline visit and covariance structure between visits was estimated without

restriction. The _P_ values denote group-by-visit interaction. The primary analysis was the mixed-model analysis, or MMRM if the mixed-model analysis failed, for the endpoints measured at

baseline and at the 6- and 12-week visits, and an unpaired _t_ test or the Mann–Whitney _U_ test was used for the endpoints measured at baseline and the 12-week visit. Statistical

significance was set at _P_ < 0.05 for all analyses. As all analyses were exploratory, and the primary analysis for each endpoint was specified, no correction for multiple comparisons was

applied. REPORTING SUMMARY Further information on research design is available in the Nature Research Reporting Summary linked to this article. DATA AVAILABILITY The datasets generated

and/or analyzed during this study are available from the corresponding author on reasonable request. REFERENCES * Niccoli, T. & Partridge, L. Ageing as a risk factor for disease. _Curr.

Biol._ 22, R741–R752 (2012). Article  CAS  PubMed  Google Scholar  * Imai, S. I. & Guarente, L. NAD+ and sirtuins in aging and disease. _Trends Cell. Biol._ 24, 464–471 (2014). Article 

CAS  PubMed  PubMed Central  Google Scholar  * Yoshino, J., Baur, J. A. & Imai, S. I. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. _Cell Metab_ 27, 513–528

(2018). Article  CAS  PubMed  Google Scholar  * Fang, E. F. et al. NAD+ in aging: molecular mechanisms and translational implications. _Trends Mol. Med._ 223, 899–916 (2017). Article  Google

Scholar  * Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. _Cell Metab_ 27, 667–676.e4 (2018). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. _Science_ 352, 1436–1443 (2016). Article  CAS  PubMed  Google Scholar

  * Trammell, S. A., Yu, L., Redpath, P., Migaud, M. E. & Brenner, C. J. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. _J. Nutr._ 146, 957–963 (2016). Article  CAS

  PubMed  PubMed Central  Google Scholar  * Mills, K. F. et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. _Cell Metab_

24, 795–806 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Trammell, S. A. et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. _Nat.

Commun._ 7, 12948 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Airhart, S. E. et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional

supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. _PLoS ONE_ 12, e0186459 (2017). Article  PubMed  PubMed Central  Google Scholar  *

Dellinger, R. W. et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled

study. _npj Aging Mech. Dis_ 3, 17 (2017). Article  PubMed  PubMed Central  Google Scholar  * Martens, C. R. et al. Chronic nicotinamide riboside supplementation is well-tolerated and

elevates NAD(+) in healthy middle-aged and older adults. _Nat. Commun._ 9, 1286 (2018). Article  PubMed  PubMed Central  Google Scholar  * Dollerup, O. L. et al. A randomized

placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. _Am. J. Clin. Nutr._ 108, 343–353 (2018). Article  PubMed

  Google Scholar  * Dolopikou, C. F. et al. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over

study. _Eur. J. Nutr._ 59, 505–515 (2020). Article  CAS  PubMed  Google Scholar  * Conze, D., Brenner, C. & Kruger, C. L. Safety and metabolism of long-term administration of NIAGEN

(nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. _Sci. Rep._ 9, 9772 (2019). Article  PubMed  PubMed Central 

Google Scholar  * Elhassan, Y. S. et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. _Cell

Rep._ 28, 1717–1728 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  * Remie, C. M. E. et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle

acetylcarnitine concentrations in healthy obese humans. _Am. J. Clin. Nutr._ 112, 413–426 (2020). Article  PubMed  PubMed Central  Google Scholar  * Simic, P. et al. Nicotinamide riboside

with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in

patients with AKI. _BMC Nephrol._ 21, 342 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  * Dollerup, O. L. et al. Nicotinamide riboside does not alter mitochondrial

respiration, content or morphology in skeletal muscle from obese and insulin-resistant men. _J. Physiol._ 598, 731–754 (2020). Article  CAS  PubMed  Google Scholar  * Irie, J. et al. Effect

of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. _Endocr. J._ 67, 153–160 (2020). Article  CAS  PubMed

  Google Scholar  * Yoshino, M. et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. _Science._ 372, 1224–1229 (2021). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Liao, B. et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. _J. Int. Soc. Sports

Nutr._ 18, 54 (2021). Article  PubMed  PubMed Central  Google Scholar  * Garavaglia, S. et al. The high-resolution crystal structure of periplasmic _Haemophilus influenzae_ NAD nucleotidase

reveals a novel enzymatic function of human CD73 related to NAD metabolism. _Biochem. J._ 441, 131–141 (2012). Article  CAS  PubMed  Google Scholar  * Mallinckrodt, C. H., Clark, W. S. &

David, S. R. Accounting for dropout bias using mixed-effects models. _J. Biopharm. Stat._ 11, 9–21 (2001). Article  CAS  PubMed  Google Scholar  * Freireich, E. J., Gehan, E. A., Rall, D.

P., Schmidt, L. H. & Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. _Cancer Chemother. Rep._ 50, 219–244 (1966). *

Guyton, J. R. & Bays, H. E. Safety considerations with niacin therapy. _Am. J. Cardiol._ 99, S22–S31 (2007). Article  Google Scholar  * Knip, M. et al. Safety of high-dose nicotinamide:

a review. _Diabetologia_ 43, 1337–1345 (2000). Article  CAS  PubMed  Google Scholar  * Shats, I. et al. Bacteria boost mammalian host NAD metabolism by engaging the deamidated biosynthesis

pathway. _Cell Metab._ 31, 564–579 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  * Goodpaster, B. H. et al. The loss of skeletal muscle strength, mass, and quality in older

adults: the health, aging and body composition study. _J. Gerontol. A Biol. Sci. Med. Sci._ 61, 1059–1064 (2006). Article  PubMed  Google Scholar  * Gomes, A. P. et al. Declining NAD(+)

induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. _Cell_ 155, 1624–1638 (2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Yamada, M. et

al. Nutritional supplementation during resistance training improved skeletal muscle mass in community-dwelling frail older adults. _J. Frailty Aging_ 1, 64–70 (2012). CAS  PubMed  Google

Scholar  * Yamada, M. et al. Prevalence of sarcopenia in community-dwelling Japanese older adults. _J. Am. Med. Dir. Assoc._ 14, 911–915 (2013). Article  PubMed  Google Scholar  * Yoshimura,

Y. et al. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia: a randomized controlled trial.

_Nutrition_ 58, 1–6 (2019). Article  CAS  PubMed  Google Scholar  * Flakoll, P. et al. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength,

functionality, body composition, and protein metabolism in elderly women. _Nutrition_ 20, 445–451 (2004). Article  CAS  PubMed  Google Scholar  * Someya, S. et al. Sirt3 mediates reduction

of oxidative damage and prevention of age-related hearing loss under caloric restriction. _Cell_ 143, 802–812 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Brown, K. D. et

al. Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss. _Cell Metab._ 20, 1059–1068 (2014). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Han, S., Du, Z., Liu, K. & Gong, S. Nicotinamide riboside protects noise-induced hearing loss by recovering the hair cell ribbon synapses. _Neurosci. Lett._ 725, 134910

(2020). Article  CAS  PubMed  Google Scholar  * Okur, M. N. et al. Short-term NAD(+) supplementation prevents hearing loss in mouse models of Cockayne syndrome. _npj Aging Mech. Dis._ 6, 1

(2020). Article  CAS  PubMed  PubMed Central  Google Scholar  * Clement, J., Wong, M., Poljak, A., Sachdev, P. & Braidy, N. The plasma NAD(+) metabolome is dysregulated in “normal”

aging. _Rejuvenation Res._ 22, 121–130 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  * Yaku, K., Okabe, K. & Nakagawa, T. Simultaneous measurement of NAD metabolome in

aged mice tissue using liquid chromatography tandem-mass spectrometry. _Biomed. Chromatogr._ 32, e4205 (2018). Article  PubMed  Google Scholar  * Yasaka, K. et al. Dose-reduced CT with

model-based iterative reconstruction in evaluations of hepatic steatosis: how low can we go? _Eur. J. Radiol._ 83, 1063–1068 (2014). Article  PubMed  Google Scholar  * Folstein, M. F.,

Folstein, S. E. & McHugh, P. R. A practical method for grading the cognitive state of patients for the clinician. _J. Psychiatr. Res._ 12, 189–198 (1975). Article  CAS  PubMed  Google

Scholar  * Nasreddine, Z. S. et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. _J. Am. Geriatr. Soc._ 53, 695–699 (2005). Article  PubMed

  Google Scholar  * Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. _Bone Marrow Transplant_ 48, 452–458 (2013). Article  CAS  PubMed 

Google Scholar  Download references ACKNOWLEDGEMENTS We thank all volunteers for participating in this study and the staff of the Clinical Research Support Center Phase 1 Unit, The

University of Tokyo Hospital for supporting this study. We also would like to thank Editage (www.editage.com) for English language editing. This study was funded by Mitsubishi Corporation

Life Sciences Limited, and the firm provided NMN. AUTHOR INFORMATION Author notes * These authors contributed equally: Masaki Igarashi, Yoshiko Nakagawa-Nagahama, Masaomi Miura. AUTHORS AND

AFFILIATIONS * Department of Diabetes & Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Masaki Igarashi, Yoshiko Nakagawa-Nagahama, Masaomi Miura, 

Naoto Kubota & Toshimasa Yamauchi * Data Science Office, Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan Kosuke Kashiwabara * Department of Molecular

and Medical Pharmacology, Faculty of Medicine, University of Toyama, Toyama, Japan Keisuke Yaku & Takashi Nakagawa * Department of Clinical Nutrition Therapy, The University of Tokyo

Hospital, The University of Tokyo, Tokyo, Japan Mika Sawada, Rie Sekine & Naoto Kubota * Mitsubishi Corporation Life Sciences Limited, Tokyo, Japan Yuichiro Fukamizu, Toshiya Sato & 

Takanobu Sakurai * Department of Radiology, Tokyo Metropolitan Police Hospital Tokyo, Tokyo, Japan Jiro Sato * Department of Radiation Technology, The University of Tokyo Hospital, Tokyo,

Japan Kenji Ino * Toranomon Hospital, Tokyo, Japan Takashi Kadowaki Authors * Masaki Igarashi View author publications You can also search for this author inPubMed Google Scholar * Yoshiko

Nakagawa-Nagahama View author publications You can also search for this author inPubMed Google Scholar * Masaomi Miura View author publications You can also search for this author inPubMed 

Google Scholar * Kosuke Kashiwabara View author publications You can also search for this author inPubMed Google Scholar * Keisuke Yaku View author publications You can also search for this

author inPubMed Google Scholar * Mika Sawada View author publications You can also search for this author inPubMed Google Scholar * Rie Sekine View author publications You can also search

for this author inPubMed Google Scholar * Yuichiro Fukamizu View author publications You can also search for this author inPubMed Google Scholar * Toshiya Sato View author publications You

can also search for this author inPubMed Google Scholar * Takanobu Sakurai View author publications You can also search for this author inPubMed Google Scholar * Jiro Sato View author

publications You can also search for this author inPubMed Google Scholar * Kenji Ino View author publications You can also search for this author inPubMed Google Scholar * Naoto Kubota View

author publications You can also search for this author inPubMed Google Scholar * Takashi Nakagawa View author publications You can also search for this author inPubMed Google Scholar *

Takashi Kadowaki View author publications You can also search for this author inPubMed Google Scholar * Toshimasa Yamauchi View author publications You can also search for this author

inPubMed Google Scholar CONTRIBUTIONS M.I., M.M., Y.F., T.Sato., and T.Sakurai. conceptualized the trial; M.I., M.M., T.K., and T.Y. designed the trial; M.I, Y.N.N., and M.M. conducted the

clinical trial; K.Y. and T.N. performed targeted metabolomics and the quantitation of NAD + -related metabolites; M.S., R.S., and N.K. provided technical support during body composition

measurement and analysis; J.S. and K.I. provided technical support in the CT experiments and assistance in CT data analysis; Y.N.N. and K.K. conducted statistical analyses. M.I., Y.N.N.,

M.M., and T.Y. interpreted the data. M.I., Y.N.N., M.M., and K.K. led the manuscript writing and figure preparation processes. All authors read and approved the final manuscript. M.I,

Y.N.N., and M.M. are co-first authors. CORRESPONDING AUTHORS Correspondence to Masaki Igarashi or Toshimasa Yamauchi. ETHICS DECLARATIONS COMPETING INTERESTS The authors Y.F., T. Sato, and

T. Sakurai declare no competing non-financial interests, but do declare the following competing financial interests: they are employees of Mitsubishi Corporation Life Sciences Limited. The

remaining authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTAL MATERIALS REPORTING SUMMARY RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original

author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the

article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use

is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Igarashi, M., Nakagawa-Nagahama, Y., Miura, M. _et al._ Chronic nicotinamide

mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. _npj Aging_ 8, 5 (2022).

https://doi.org/10.1038/s41514-022-00084-z Download citation * Received: 17 September 2021 * Accepted: 17 March 2022 * Published: 01 May 2022 * DOI:

https://doi.org/10.1038/s41514-022-00084-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative